A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure-Reference-Cited by-同舟云学术

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

Published:2014-12 Issue:12 Volume:38 Page:1430-1434
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Thepot Sylvain,Boehrer Simone,Seegers Valérie,Prebet Thomas,Beyne-Rauzy Odile,Wattel Eric,Delaunay Jacques,Raffoux Emmanuel,Hunault Mathilde,Jourdan Eric,Chermat Fatiha,Sebert Marie,Kroemer Guido,Fenaux Pierre,Adès Lionel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

2. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure;Prebet;J Clin Oncol,2011

3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study;Boehrer;Blood,2008

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells;Cancer Research;2023-12-14

2. Identification of a signature based on non‐apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia;British Journal of Haematology;2022-12-09

3. Is the EGFR pathway relevant for the pathogenesis but not for treatment of acute myeloid leukemia?;Journal of Cancer Metastasis and Treatment;2021

4. Turning liabilities into opportunities: Off-target based drug repurposing in cancer;Seminars in Cancer Biology;2021-01

5. Erlotinib is effective against FLT3‐ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn;The FASEB Journal;2020-06-15